Revvity (RVTY)'s recent
share price weakness has garnered attention, given its
DCF valuation gap.
New York Life Investment Management LLC and Diamond Hill Capital Management Inc. increased their holdings, while JP Morgan boosted its price target to $105. Despite a one-off US$92.7m loss, the company's Q4 2025 sales exceeded estimates. With the unveiling of its
SLAS2026 platforms,
automation expansion, and an upcoming projected
earnings report, Revvity showcases promising
growth potential. Financial results and a recent share price rebound show a
valuation check. The unveiling of its new
Imaging Innovation Center, a partnership with
Eli Lilly involving AI technology development, has boosted its innovation score. Q3 2025 earnings call highlights included strong software growth and strategic initiatives. Despite market fluctuations, Revvity continued to trade higher, based on earnings guidance above consensus.
Revvity RVTY News Analytics from Mon, 28 Jul 2025 07:00:00 GMT to Sat, 14 Feb 2026 13:13:27 GMT -
Rating 6
- Innovation 5
- Information 7
- Rumor -3
